| Name | Rilpivirine |
| Description | Rilpivirine (R278474) is a diarylpyrimidine derivative and reverse transcriptase inhibitor with antiviral activity against HIV-1 that is used in the treatment of HIV infections. |
| In vitro | Rilpivirine, dissolved in PEG 400 and administered via intravenous injection at dosages of 4 mg/kg in rats and 1.25 mg/kg in dogs, exhibits half-lives of 4.4 hours and 31 hours, respectively. |
| In vivo | Rilpivirine demonstrates antiviral activity against both wild-type and selective point single and double HIV-1 mutants, with an effective concentration (EC50) ranging from 0.1 to 2 nM. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.85 mg/mL (18.69 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2.5 mg/mL (6.82 mM), Sonication is recommended.
|
| Keywords | wild-type | transcriptase | TMC-278 | TMC 278 | Rilpivirine | ReverseTranscriptase | Reverse Transcriptase | reverse | resistance | R-278474 | R 278474 | non-nucleoside | NNRTI | mutant | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | diarylpyrimidine | DB-08864 | DB 08864 | DAPY | antiviral |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Lamivudine | Chloroquine phosphate | Valproic Acid | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |